Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
نویسندگان
چکیده
منابع مشابه
Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
Individuals who carry an inherited mutation in the breast cancer 1 (BRCA1) and BRCA2 genes have a significant risk of developing breast and ovarian cancer over the course of their lifetime. As a result, there are important considerations for the clinician in the counseling, followup and management of mutation carriers. This review outlines salient aspects in the approach to patients at high ris...
متن کاملBreast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Men who carry germline mutations in the BRCA2 gene have a higher risk of developing breast carcinoma than men in the general population. Men who carry germline mutations in the BRCA1 gene may also be at a higher risk for breast carcinoma, but this association is not as well established. We evaluated the risks of developing breast carcinoma for male BRCA1 and BRCA2 mutation carriers in the US po...
متن کاملBRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
BACKGROUND Understanding the effect of oral contraceptives on risk of breast cancer in BRCA1 or BRCA2 mutation carriers is important because oral contraceptive use is a common, modifiable practice. METHODS We studied 497 BRCA1 and 307 BRCA2 mutation carriers, of whom 195 and 128, respectively, had been diagnosed with breast cancer. Case-control analyses were conducted using unconditional logi...
متن کاملOvarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival
OBJECTIVES To compare clinical-pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC). METHODS Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA+) and a control group of 64 age-matched patients with no family history of b...
متن کاملPlasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA mutation carriers. Whether low OPG levels contribute to the high breast cancer risk in this populatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Prevention
سال: 2021
ISSN: 0959-8278
DOI: 10.1097/cej.0000000000000664